{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:17Z","timestamp":1761894677631},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,1,10]],"date-time":"2008-01-10T00:00:00Z","timestamp":1199923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>JAK2<\/jats:italic>V617F\u2010positive patients with essential thrombocythemia, as opposed to their mutation\u2010negative counterparts, require lower doses of hydroxyurea (HU) for control of their platelet count. In the current study, we looked for predictors of HU response in 69 patients with primary myelofibrosis (PMF) and 56 with polycythemia vera (PV). <jats:italic>JAK2<\/jats:italic>V617F analysis was performed on bone marrow\u2010derived DNA obtained at or near the time of diagnosis. HU response in PMF was associated with a shorter disease duration (<jats:italic>P<\/jats:italic> = 0.008), absence of previous therapy (<jats:italic>P<\/jats:italic> = 0.01), older age at diagnosis (<jats:italic>P<\/jats:italic> = 0.009), and presence of <jats:italic>JAK2<\/jats:italic>V617F (<jats:italic>P<\/jats:italic> = 0.02). On multivariable analysis, only the latter retained its significance (48% vs. 8% response in mutation positive vs. negative cases). In PV, <jats:italic>JAK2<\/jats:italic>V617F allele burden correlated directly with HU response (<jats:italic>P<\/jats:italic> = 0.05) and inversely with daily HU dose in responding patients (<jats:italic>P<\/jats:italic> = 0.02). The current study suggests that <jats:italic>JAK2<\/jats:italic>V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV. Am. J. Hematol., 2008. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21149","type":"journal-article","created":{"date-parts":[[2008,2,11]],"date-time":"2008-02-11T17:47:22Z","timestamp":1202752042000},"page":"363-365","source":"Crossref","is-referenced-by-count":32,"title":["The presence of <i>JAK2<\/i>V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea"],"prefix":"10.1002","volume":"83","author":[{"given":"Shireen","family":"Sirhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,2,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.5.3919"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404810"},{"key":"e_1_2_1_5_2","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)\u2010negative myeloproliferative disorders","author":"Pietra D","journal-title":"Blood"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2210"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4824"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601462103"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06348.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404749"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2007-0175"},{"key":"e_1_2_1_15_2","article-title":"Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders","author":"Pardanani A","journal-title":"Blood"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083501"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22663"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054940"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-064287"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21645"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404854"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404724"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05776.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3395"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099184"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.1013.1013"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404948"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-038968"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.moh.0000208469.48614.2e"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3503164.x"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404750"},{"key":"e_1_2_1_35_2","first-page":"17","volume-title":"World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues","author":"Vardiman JW","year":"2001"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404710"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404007"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21149","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T12:37:24Z","timestamp":1696682244000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1002\/ajh.21149"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21149","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,11]]}}}